Abstract: A method of producing 1-epi-2-deoxyfortimicin A, key intermediates therefor and an improved process for synthesizing the key intermediate 1,2-di-epi-fortimicin A.
Abstract: A 1,2-carbamate of fortimicin B and derivatives represented by the formula: ##STR1## wherein: R is hydrogen or monocyclicaryloxycarbonyl, R.sub.1 is hydrogen or monocyclicaryloxycarbonyl; and R.sub.2 is selected from the group consisting of loweralkyl, loweralkoxycarbonyl aminoloweralkyl, hydroxyloweralkyl, hydroxy-substituted aminolowerakyl, an amino acid residue, and N-protected amino acid residue, or when R and R.sub.1 are hydrogen, R.sub.2 can also be hydrogen; and the acid addition salts thereof when R,R.sub.1 or R.sub.2 are hydrogen or an unprotected aminoacid residue.
Abstract: By condensation of anisoyl chloride with 2,3-dichloroanisole under proper conditions, 2,3-dichloro-4-(hydroxybenzoyl)phenol is obtained directly.
Type:
Grant
Filed:
August 9, 1979
Date of Patent:
May 19, 1981
Assignee:
Abbott Laboratories
Inventors:
Anthony K. L. Fung, Donald E. Morrison, Andre G. Pernet
Abstract: Highly water-soluble erythromycin A derivatives wherein the desosamine moiety is quaternized with an acyloxy-, benzoyloxy- or alkoxycarbonyl-(or carboxy)-acylmethyl iodide, bromine or chloride and esterified in the 2-position with loweralkyl or --(CH.sub.2).sub.n CO.sub.2 R", wherein R" is H, loweralkyl or substituted loweralkyl and n is an integer from 1-5. These new esters readily convert to erythromycin A upon administration to warm-blooded animals.
Abstract: It has been found that dipeptides containing a 3-halo-D-alanine C-terminus are powerful antibacterials and produce a highly useful synergistic effect with antibiotics.
Type:
Grant
Filed:
June 9, 1980
Date of Patent:
April 28, 1981
Assignee:
Abbott Laboratories
Inventors:
Daniel I. Chu, Jerry R. Martin, Alford M. Thomas, Norman E. Wideburg
Abstract: A fortimicin intermediate selected from the group consisting of 1,2',6'-tri-N-benzyloxycarbonylfortimicin B-4,5-carbamate and 1,2',6'-tri-N-acetylfortimicin A-4,5-carbamate. The compounds are useful as intermediates in the preparation of 2-epi-fortimicin B.
Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The equipment sets of this invention have a primary tube valve controlled by pilot liquid diverted from the secondary liquid flow path.
Type:
Grant
Filed:
February 28, 1979
Date of Patent:
March 31, 1981
Assignee:
Abbott Laboratories
Inventors:
Jack L. Harms, Joseph N. Genese, Andrew J. Muetterties
Abstract: Gravitational flow system and equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted.
Type:
Grant
Filed:
February 28, 1979
Date of Patent:
March 17, 1981
Assignee:
Abbott Laboratories
Inventors:
Andrew J. Muetterties, Joseph N. Genese
Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention have a tube of reduced diameter to restrict the flow of primary liquid to a predetermined rate.
Type:
Grant
Filed:
February 28, 1979
Date of Patent:
March 17, 1981
Assignee:
Abbott Laboratories
Inventors:
John J. Leahey, Andrew J. Muetterties, Joseph N. Genese
Abstract: The use of catalytic amounts of tris(3-dimethylaminopropyl)amine promotes the formation of urethane linkages. Its unusual activity and properties make this compound very useful in the manufacture of rigid polyurethanes.
Type:
Grant
Filed:
September 24, 1979
Date of Patent:
March 10, 1981
Assignee:
Abbott Laboratories
Inventors:
Daniel S. Raden, Chala V. Maripuri, Frank C. Becker
Abstract: 5H-[1]Benzopyrano[3,4-d]pyridines represented by the formula ##STR1## wherein each R.sub.1 is loweralkyl, R.sub.2 is alkyl, cycloalkyl or ##STR2## wherein Y is a straight or branched chain alkylene group having from 1 to 10 carbon atoms and each R.sub.4, R.sub.5 and R.sub.6 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl; and R.sub.3 is hydroxy, acyloxy, loweralkoxy, loweralkenyloxy, loweralkynyloxy or ##STR3## X is a straight or branched chain alkylene group having from one to eight carbon atoms, and wherein R.sub.7 and R.sub.8 are the same or different members of the group consisting of hydrogen or loweralkyl, or ##STR4## wherein X is a straight or branched chain alkylene group having from one to eight carbon atoms, a is an integer from 1 to 4, b is an integer from 1 to 4, Z is CH.sub.2, O, S or NR.sub.10 with R.sub.10 being hydrogen or loweralkyl, with the limitation that when Z is O or S, the sum of a and b is 3 or 4; and when Z is NR.sub.
Abstract: 2',6'-Di-N-benzyloxycarbonylfortimicin B-1,2:4,5-bis-carbamate and fortimicin B-1,2:4,5-bis-carbamate and its salt are provided by the present invention. The compound is represented by the formula ##STR1## wherein each R is either hydrogen or benzyloxycarbonyl The bis-carbamate is useful as in intermediate in the preparation of fortamine bis-carbamate, which in turn is useful as an intermediate in the preparation of aminoglycoside antibiotics via glycosidation with suitably protected sugar moieties.
Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention employ a novel flexible diaphragm valve as the air barrier.
Type:
Grant
Filed:
February 28, 1979
Date of Patent:
February 24, 1981
Assignee:
Abbott Laboratories
Inventors:
Joseph N. Genese, Andrew J. Muetterties
Abstract: Gravitational flow system and equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention employ a combined air barrier and liquid sequencing valve.
Abstract: An improved anti-hypertensive agent, the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine dihydrate.
Abstract: The present invention provides 2-deoxy-3-O-demethyl-fortimcins A and B and the 4-N-acyl and alkyl derivatives thereof, represented by the formula: ##STR1## wherein R is selected from the group consisting of hydrogen, acyl, aminoacyl,diaminoacyl,N-monoloweralkylaminoalkyl,N,N-diloweralkylaminoalky l, hydroxy-substituted aminoacyl,loweralkyl, aminoloweralkyl, N-monoloweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl and hydroxy-substituted aminoloweralkyl and the pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
September 26, 1979
Date of Patent:
February 17, 1981
Assignee:
Abbott Laboratories
Inventors:
Jerry R. Martin, John S. Tadanier, Paulette Johnson
Abstract: Disclosed are 2-deoxy-2-substituted fortimicin A and B derivatives represented by the formula ##STR1## wherein R is hydrogen glycyl, .beta.-alanyl, acetyl, or .beta.-amino lower alkyl, R.sub.1 is hydrogen, amino, azido, halo, glycylamido, .beta.-alanyl amido or 2-O-methanesulfonyl and R.sub.2 is hydrogen or halo and their pharmaceutically acceptable salts. The compounds are active antibacterial agents.
Type:
Grant
Filed:
September 26, 1979
Date of Patent:
February 10, 1981
Assignee:
Abbott Laboratories
Inventors:
Jerry R. Martin, John S. Tadanier, Paulette Johnson, Alex M. Nadzan